What is the current cost of COPD (Chronic Obstructive Pulmonary Disease) therapies?

Medicines in the COPD Ellipta portfolio are highlighted in orange on the graph below:

- **Incruse Ellipta** (umeclidinium) is a LAMA indicated as a maintenance bronchodilator treatment to relieve symptoms in adult patients with COPD.1
- **Anoro Ellipta** (umeclidinium/vilanterol) is a LAMA/LABA indicated as a maintenance bronchodilator treatment to relieve symptoms in adult patients with COPD.2
- **Relvar Ellipta** (fluticasone furoate/vilanterol) is an ICS/LABA indicated for the symptomatic treatment of adults with COPD with a FEV1<70% predicted normal (post-bronchodilator) with an exacerbation history despite regular bronchodilator therapy.3
- **Trelegy Ellipta** (fluticasone furoate/umeclidinium/vilanterol) is an ICS/LAMA/LABA indicated as a maintenance treatment for adult patients with moderate to severe COPD who are not adequately treated by a combination of an ICS and a LABA or a LAMA and a LABA.4

30-day acquisition cost based on List Price: Maintenance Therapies for the Treatment of COPD5,6

---

**Reference:** Dictionary of Medicines and Devices (https://apps.nhsbsa.nhs.uk/DMDBrowser/DMDBrowser.do). All other prices obtained from eMIMS (http://www.mims.co.uk). Please note: All formoterol preparations are assumed to be dosed at 12mcg twice a day. This information is sensitive to price changes. The drug costs here are based on list prices and information for currently available COPD therapies were last updated on 20/01/2020. Drug costs and information for currently available COPD therapies is reviewed monthly. Prescribing decisions should not be based on cost alone. You should refer to the SPC of each medicine for further information such as indications, contraindications, precautions and adverse events.

What potential cost savings could the Ellipta range of medicines offer in your locality?

A GSK Regional Account Manager can demonstrate potential cost savings that the Ellipta range of medicines can offer your local health economy or health care system. To arrange an appointment with a Regional Account Manager to discuss in person, via telephone or video call please: Live Chat: https://gskpro.com/en-gb/contact-us/live-chat/

---

LAMA = long-acting muscarinic antagonist; LABA = long-acting β-agonist; ICS = Inhaled corticosteroid
Incruse, Anoro, Relvar, Seretide, Trelegy and Ellipta are registered trademarks of the GlaxoSmithKline Group of companies Trelegy Ellipta, Anoro Ellipta & Relvar Ellipta were developed in collaboration with INNOVIVA
Incruse Ellipta Summary of Product Characteristics. GlaxoSmithKline
Anoro Ellipta Summary of Product Characteristics. GlaxoSmithKline
Relvar Ellipta Summary of Product Characteristics. GlaxoSmithKline
Trelegy Ellipta Summary of Product Characteristics. GlaxoSmithKline
Monthly Index of Medical Specialties Online. [Accessed January 2020]

### Incruse ▼ Ellipta (umeclidinium) Prescribing Information

(Please consult the full Summary of Product Characteristics (SmPC) before prescribing)

Click here to view the Incruse ▼ Ellipta prescribing information

Adverse events should be reported. Reporting forms and information can be found at www.mhra.gov.uk/yellowcard or search for MHRA Yellowcard in the Google Play or Apple App store. Adverse events should also be reported to GlaxoSmithKline on 0800 221 441

### Anoro ▼ Ellipta (umeclidinium/vilanterol) Prescribing Information

(Please consult the full Summary of Product Characteristics (SmPC) before prescribing)

Click here to view the Anoro ▼ Ellipta prescribing information

### Relvar Ellipta (fluticasone furoate/vilanterol) Prescribing Information

(Please consult the full Summary of Product Characteristics (SmPC) before prescribing)

Click here to view the Relvar Ellipta prescribing information

### Trelegy ▼ Ellipta (fluticasone furoate/umeclidinium/vilanterol) Prescribing Information

(Please consult the full Summary of Product Characteristics (SmPC) before prescribing)

Click here to view the Trelegy ▼ Ellipta prescribing information

### Seretide (salmeterol xinafoate/fluticasone propionate) Prescribing Information

(Please consult the full Summary of Product Characteristics (SmPC) before prescribing)

Click here to view the Seretide prescribing information

Incruse, Anoro, Relvar, Seretide, Trelegy and Ellipta are registered trademarks of the GlaxoSmithKline Group of companies